Lung cancer claims more lives than any other cancer. The expected
five-year survival rate for all patients diagnosed with lung cancer is 15
percent; the five-year survival rate for cases detected when the disease is
still localized is 50 percent. Presently, only 16 percent of lung cancer
cases are diagnosed at this early stage.
Biomoda's technology was originally developed at Los Alamos National
For more information contact:
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Biomoda's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. Biomoda, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Biomoda's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
|SOURCE Biomoda, Inc.|
Copyright©2008 PR Newswire.
All rights reserved